Cargando…

Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating cancer due to its poor survival rate, early detection, and resectability. This study aimed to determine the peripheral blood mononuclear cell (PBMC) immune biomarkers in patients with PDAC and investigate the PDAC-specific per...

Descripción completa

Detalles Bibliográficos
Autores principales: Jang, Sung Ill, Lee, Hyung Keun, Chang, Eun-Ju, Kim, Somi, Kim, So Young, Hong, In Young, Kim, Jong Kyoung, Lee, Hye Sun, Yang, Juyeon, Cho, Jae Hee, Lee, Dong Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361912/
https://www.ncbi.nlm.nih.gov/pubmed/37165046
http://dx.doi.org/10.1007/s00262-023-03458-8
_version_ 1785076310659301376
author Jang, Sung Ill
Lee, Hyung Keun
Chang, Eun-Ju
Kim, Somi
Kim, So Young
Hong, In Young
Kim, Jong Kyoung
Lee, Hye Sun
Yang, Juyeon
Cho, Jae Hee
Lee, Dong Ki
author_facet Jang, Sung Ill
Lee, Hyung Keun
Chang, Eun-Ju
Kim, Somi
Kim, So Young
Hong, In Young
Kim, Jong Kyoung
Lee, Hye Sun
Yang, Juyeon
Cho, Jae Hee
Lee, Dong Ki
author_sort Jang, Sung Ill
collection PubMed
description BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating cancer due to its poor survival rate, early detection, and resectability. This study aimed to determine the peripheral blood mononuclear cell (PBMC) immune biomarkers in patients with PDAC and investigate the PDAC-specific peripheral blood biomarker panel and validate its clinical performance. METHODS: In this prospective, blinded, case–control study, a biomarker panel formula was generated using a development cohort—including healthy controls, patients at high risk of PDAC, and patients with benign pancreatic disease, PDAC, or other gastrointestinal malignancies—and its diagnostic performance was verified using a validation cohort, including patients with ≥ 1 lesion suspected as PDAC on computed tomography (CT). RESULTS: RNA-sequencing of PBMCs from patients with PDAC identified three novel immune cell markers, IL-7R, PLD4, and ID3, as specific markers for PDAC. Regarding the diagnostic performance of the regression formula for the three biomarker panels, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 84.0%, 78.8%, 47.2%, 95.6%, and 79.8%, respectively. Based on the formula scores for the biomarker panel, the false-negative rate (FNR) of the biomarkers was 8% (95% confidence interval [CI] 3.0–13.0), which was significantly lower than that based on CT in the validation cohort (29.2%, 95% CI 20.8–37.6). CONCLUSIONS: The regression formula constructed using three PBMC biomarkers is an inexpensive, rapid, and convenient method that shows clinically useful performance for the diagnosis of PDAC. It aids diagnoses and differential diagnoses of PDAC from pancreatic disease by lowering the FNR compared to CT. Clinical trial registration Clinical Research Information Service, KCT0004614 (08 January 2020). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-023-03458-8.
format Online
Article
Text
id pubmed-10361912
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103619122023-07-23 Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing Jang, Sung Ill Lee, Hyung Keun Chang, Eun-Ju Kim, Somi Kim, So Young Hong, In Young Kim, Jong Kyoung Lee, Hye Sun Yang, Juyeon Cho, Jae Hee Lee, Dong Ki Cancer Immunol Immunother Research BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains a devastating cancer due to its poor survival rate, early detection, and resectability. This study aimed to determine the peripheral blood mononuclear cell (PBMC) immune biomarkers in patients with PDAC and investigate the PDAC-specific peripheral blood biomarker panel and validate its clinical performance. METHODS: In this prospective, blinded, case–control study, a biomarker panel formula was generated using a development cohort—including healthy controls, patients at high risk of PDAC, and patients with benign pancreatic disease, PDAC, or other gastrointestinal malignancies—and its diagnostic performance was verified using a validation cohort, including patients with ≥ 1 lesion suspected as PDAC on computed tomography (CT). RESULTS: RNA-sequencing of PBMCs from patients with PDAC identified three novel immune cell markers, IL-7R, PLD4, and ID3, as specific markers for PDAC. Regarding the diagnostic performance of the regression formula for the three biomarker panels, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 84.0%, 78.8%, 47.2%, 95.6%, and 79.8%, respectively. Based on the formula scores for the biomarker panel, the false-negative rate (FNR) of the biomarkers was 8% (95% confidence interval [CI] 3.0–13.0), which was significantly lower than that based on CT in the validation cohort (29.2%, 95% CI 20.8–37.6). CONCLUSIONS: The regression formula constructed using three PBMC biomarkers is an inexpensive, rapid, and convenient method that shows clinically useful performance for the diagnosis of PDAC. It aids diagnoses and differential diagnoses of PDAC from pancreatic disease by lowering the FNR compared to CT. Clinical trial registration Clinical Research Information Service, KCT0004614 (08 January 2020). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-023-03458-8. Springer Berlin Heidelberg 2023-05-10 2023 /pmc/articles/PMC10361912/ /pubmed/37165046 http://dx.doi.org/10.1007/s00262-023-03458-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Jang, Sung Ill
Lee, Hyung Keun
Chang, Eun-Ju
Kim, Somi
Kim, So Young
Hong, In Young
Kim, Jong Kyoung
Lee, Hye Sun
Yang, Juyeon
Cho, Jae Hee
Lee, Dong Ki
Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing
title Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing
title_full Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing
title_fullStr Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing
title_full_unstemmed Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing
title_short Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing
title_sort improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mrna sequencing and single-cell rna-sequencing
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361912/
https://www.ncbi.nlm.nih.gov/pubmed/37165046
http://dx.doi.org/10.1007/s00262-023-03458-8
work_keys_str_mv AT jangsungill improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing
AT leehyungkeun improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing
AT changeunju improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing
AT kimsomi improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing
AT kimsoyoung improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing
AT honginyoung improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing
AT kimjongkyoung improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing
AT leehyesun improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing
AT yangjuyeon improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing
AT chojaehee improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing
AT leedongki improvedpredictabilityofpancreaticductaladenocarcinomadiagnosisusingabloodimmunecellbiomarkerpaneldevelopedfrombulkmrnasequencingandsinglecellrnasequencing